Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 81 to 90 of 330

TitleReference numberPublishedLast updated
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancerHTG681
Transperineal biopsy for diagnosing prostate cancerHTG680
MRI fusion biopsy systems for diagnosing prostate cancerHTG678
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Focal therapy using high-intensity focused ultrasound for localised prostate cancerHTG667

Results per page

  1. 10
  2. 25
  3. 50
  4. All